Michael Parker

Michael Parker

Auto-generated profile, based on publicly available information

Michael Parker

Ethox Centre, Nuffield Department of Population Health, University of Oxford, Oxford, UK

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 February 2025 in Nature
Verified
Journal Article
Closed access
PDF file
MKMoritz U. G. Kraemer
Moritz U. G. Kraemer
JTJoseph L.-H. Tsui
Joseph L.-H. Tsui
SCSerina Y. Chang
Serina Y. Chang
SLSpyros Lytras
Spyros Lytras
MKMark P. Khurana
Mark P. Khurana
SBSamir Bhatt
Samir Bhatt

13 October 2016 in PLOS ONE
Verified
Journal Article
Open access
PDF file
MPMichael Parker
Michael Parker
PKPatricia Kingori
Patricia Kingori
There has been a dramatic rise in the scale and scope of collaborative global health research. A number of structural and scientific factors explain this growth and there has been much discussion of these in the literature. Little, if any, attention has been paid, however, to the factors identified by scientists and other research actors as important to successful research collaboration. This is surprising given that their decisions are likely to play a key role in the sustainability and effectiveness of global health research initiatives. In this paper, we report on qualitative research with leading scientists involved in major international research collaborations about their views on good and bad collaborations and the factors that inform their decision-making about joining and participating actively in research networks. We identify and discuss eight factors that researchers see as essential in judging the merits of active participation in global health research collaborations: opportunities for active involvement in cutting-edge, interesting science; effective leadership; competence of potential partners in and commitment to good scientific practice; capacity building; respect for the needs, interests and agendas of partners; opportunities for discussion and disagreement; trust and confidence; and, justice and fairness in collaboration. Our findings suggest that the sustainability and effectiveness of global health research collaborations has an important ethical or moral dimension for the research actors involved.

4 May 2020 in Journal of Medical Ethics
Verified
Journal Article
Open access
PDF file
MPMichael J Parker
Michael J Parker
CFChristophe Fraser
Christophe Fraser
LALucie Abeler-Dörner
Lucie Abeler-Dörner
DBDavid Bonsall
David Bonsall
In this paper we discuss ethical implications of the use of mobile phone apps in the control of the COVID-19 pandemic. Contact tracing is a well-established feature of public health practice during infectious disease outbreaks and epidemics. However, the high proportion of pre-symptomatic transmission in COVID-19 means that standard contact tracing methods are too slow to stop the progression of infection through the population. To address this problem, many countries around the world have deployed or are developing mobile phone apps capable of supporting instantaneous contact tracing. Informed by the on-going mapping of ‘proximity events’ these apps are intended both to inform public health policy and to provide alerts to individuals who have been in contact with a person with the infection. The proposed use of mobile phone data for ‘intelligent physical distancing’ in such contexts raises a number of important ethical questions. In our paper, we outline some ethical considerations that need to be addressed in any deployment of this kind of approach as part of a multidimensional public health response. We also, briefly, explore the implications for its use in future infectious disease outbreaks.

18 March 2011 in BMC Medical Ethics
Verified
Journal Article
Open access
PDF file
JVJantina de Vries
Jantina de Vries
SBSusan J Bull
Susan J Bull
ODOgobara Doumbo
Ogobara Doumbo
MIMuntaser Ibrahim
Muntaser Ibrahim
OMOdile Mercereau-Puijalon
Odile Mercereau-Puijalon
MPMichael Parker
Michael Parker
Genome-wide association studies (GWAS) provide a powerful means of identifying genetic variants that play a role in common diseases. Such studies present important ethical challenges. An increasing number of GWAS is taking place in lower income countries and there is a pressing need to identify the particular ethical challenges arising in such contexts. In this paper, we draw upon the experiences of the MalariaGEN Consortium to identify specific ethical issues raised by such research in Africa, Asia and Oceania.

12 April 2015 in BMC Medical Ethics
Verified
Journal Article
Open access
PDF file
PTPaulina Tindana
Paulina Tindana
JVJantina de Vries
Jantina de Vries
MCMegan Campbell
Megan Campbell
KLKatherine Littler
Katherine Littler
JSJanet Seeley
Janet Seeley
MPMichael Parker
Michael Parker
Community engagement has been recognised as an important aspect of the ethical conduct of biomedical research, especially when research is focused on ethnically or culturally distinct populations. While this is a generally accepted tenet of biomedical research, it is unclear what components are necessary for effective community engagement, particularly in the context of genomic research in Africa. We conducted a review of the published literature to identify the community engagement strategies that can support the successful implementation of genomic studies in Africa. Our search strategy involved using online databases, Pubmed (National Library of Medicine), Medline and Google scholar. Search terms included a combination of the following: community engagement, community advisory boards, community consultation, community participation, effectiveness, genetic and genomic research, Africa, developing countries. A total of 44 articles and 1 thesis were retrieved of which 38 met the selection criteria. Of these, 21 were primary studies on community engagement, while the rest were secondary reports on community engagement efforts in biomedical research studies. 34 related to biomedical research generally, while 4 were specific to genetic and genomic research in Africa. We concluded that there were several community engagement strategies that could support genomic studies in Africa. While many of the strategies could support the early stages of a research project such as the recruitment of research participants, further research is needed to identify effective strategies to engage research participants and their communities beyond the participant recruitment stage. Research is also needed to address how the views of local communities should be incorporated into future uses of human biological samples. Finally, studies evaluating the impact of CE on genetic research are lacking. Systematic evaluation of CE strategies is essential to determine the most effective models of CE for genetic and genomic research conducted in African settings.

15 July 2004 in BMJ
Verified
Journal Article
Closed access
PDF file
MPMichael Parker
Michael Parker
ALAnneke Lucassen
Anneke Lucassen
Case history Helen Cross's 4 year old son has just had Duchenne's muscular dystrophy diagnosed. Genetic testing confirms the diagnosis and shows that she is a carrier for the mutation. Mrs Cross's sister, Penelope Yates, is 10 weeks pregnant. Mrs Yates's obstetrician referred her to the genetics team after she told him that her nephew had speech and development delay. She told him that although she was not close to her sister and had not discussed it with her, she was concerned about the implications for her own pregnancy. In her discussions with the clinical geneticist (who did not know at this stage that both sisters were patients in the same clinic) Mrs Yates made it clear that she would consider terminating a pregnancy if she knew that the fetus was affected with a serious inherited condition. Speech and development delay are features of several conditions and would not of themselves indicate carrier testing for Duchenne's muscular dystrophy. In addition, because the Duchenne gene is large and several possible mutations exist, testing without information about which mutation is responsible for the nephew's condition is unlikely to be informative. At her next meeting with her clinical geneticist, Mrs Cross says that she knows that her sister is pregnant and that she understands that her sister's baby could be affected. She says that she has not discussed this with her sister, partly because they don't really get on but also because she suspects that if her sister were to find out, and if the fetus turned out to be affected, she would terminate the pregnancy. Mrs Cross feels strongly that this would be wrong. She knows that her sister does not share her views, but Mrs Cross says she has thought long and hard about the issues and has decided that she wants her test results and information about her son to remain confidential. Chromosomes of female carrier of Duchenne's muscular dystrophy Credit: WESSEX REGIONAL CENTRE FOR GENETICS/WELLCOME TRUST Duchenne's muscular dystrophy Duchenne's muscular dystrophy is a severe, debilitating, and progressive muscle wasting disease. Affected children become confined to a wheelchair by their early teens and usually die in their 20s. It is an X linked recessive genetic condition, and although girls carry the gene, they are not (with rare exceptions) affected. Women who are carriers have a 50% chance of passing it on to their sons.1